Trial · NCT05346393
HRS-AKI Treatment With TIPS in Patients With Cirrhosis
NCT05346393, Not applicable, Recruiting, Jena University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HRS-AKI Treatment With TIPS in Patients With Cirrhosis. Trials, record NCT05346393. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05346393
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HRS-AKI Treatment With TIPS in Patients With Cirrhosis
- NCT number
- NCT05346393
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 124 participants, estimated
- Lead sponsor
- Jena University Hospital
- Conditions
- Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic
- Interventions
- TIPS, Standard of Care
- First posted
- 2022-04-26
- Last updated
- 2024-11-18
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 12 month Liver transplant-free survival | 12 months after Baseline | 12 month Liver transplant-free survival |
| Secondary | 3-month liver transplant free survival | 3 months after Baseline | 3-month liver transplant free survival |
| Secondary | Number of patient which develop an indication for TIPS placement (variceal bleeding or refractory ascites) or TIPS revision (variceal bleeding or development of ascites) during follow-up | within 12 months after Baseline | Number of patient which develop an indication for TIPS placement according to clinical guidelines (such as variceal bleeding or refractory ascites) in the control group or indication for a TIPS revision (variceal bleeding, development of ascites) in the intervention group will be assessed during the 12 months follow-up |
| Secondary | Development of further decompensation of HRS-AKI during follow-up | within 12 months after Baseline | Development of further decompensation as defined in the Baveno VII Consensus Workshop (e.g. overt hepatic encephalopathy, refractory or recurrent ascites, dilutional hyponatremia, new AKI-HRS, variceal bleeding) during follow-up |
| Secondary | Reversal of HRS-AKI-AKI 3 MFU | 3 months after Baseline | Reversal of HRS-AKI-AKI at 3 months (vs. baseline), defined as return of serum creatinine level within 0.3 mg/dl (26 mmol/L). |
| Secondary | Reversal of HRS-AKI-AKI 12 MFU | 12 months after Baseline | Reversal of HRS-AKI-AKI at 12 months (vs. baseline), defined as return of serum creatinine level within 0.3 mg/dl (26 mmol/L). |
| Secondary | Partial response to treatment 3 MFU | 3 months after Baseline | Partial response to treatment at 3 months (vs. baseline) defined as reduction of at least one AKI stage with decrease of serum creatinine to ≥ 0.3 mg/dl (26 mmol/L) above the baseline value. |
| Secondary | Partial response to treatment 12 MFU | 12 months after Baseline | Partial response to treatment at 12 months (vs. baseline) defined as reduction of at least one AKI stage with decrease of serum creatinine to ≥ 0.3 mg/dl (26 mmol/L) above the baseline value. |
| Secondary | In-hospital survival | baseline until 12 months | In-hospital survival of the patients (patients are hospitalized for diagnosis of HRS-AKI and start of treatment - due to poor diagnosis, patients may die during hospital stay) |
| Secondary | 28-day survival | baseline until day 28 after baseline | 28-day survival |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05346393
GET https://conductscience.org/api/trials/v1/NCT05346393/registered?page=2